Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • Specialties
  • Oncology
  • Page 38
Personalizing Oxaliplatin Dosing: Reducing Neurotoxicity in Stage III Colon Cancer—Insights from the LEANOX Trial
Posted inClinical Updates news Oncology Specialties

Personalizing Oxaliplatin Dosing: Reducing Neurotoxicity in Stage III Colon Cancer—Insights from the LEANOX Trial

Posted by MedXY By MedXY 08/07/2025
LBM-based oxaliplatin dosing significantly reduces peripheral neurotoxicity without compromising survival outcomes in adjuvant treatment for stage III colon cancer.
Read More
Surgery versus Radiofrequency Ablation for Small Hepatocellular Carcinoma: Insights from the SURF-RCT and SURF-Cohort Trials
Posted inClinical Updates General Surgery news Oncology Specialties

Surgery versus Radiofrequency Ablation for Small Hepatocellular Carcinoma: Insights from the SURF-RCT and SURF-Cohort Trials

Posted by MedXY By MedXY 08/07/2025
The SURF trials found no significant difference in survival or recurrence between surgery and radiofrequency ablation for small hepatocellular carcinoma, supporting both as valid first-line options.
Read More
Posted inClinical Updates Oncology Specialties Urology

PARP inhibitors shine: How the TALAPRO-2 trial is changing the landscape of prostate cancer with precision medicine

Posted by Paul Chang By Dr.Paul 08/07/2025
Treatment for advanced prostate cancer has advanced significantly in the past decade, but metastatic castration-resistant…
Read More
No Added Survival Benefit from Adjuvant Chemotherapy in Older Women with Genomically High-Risk Hormone Receptor-Positive Breast Cancer: Results from the ASTER 70s Trial
Posted inClinical Updates Oncology Specialties

No Added Survival Benefit from Adjuvant Chemotherapy in Older Women with Genomically High-Risk Hormone Receptor-Positive Breast Cancer: Results from the ASTER 70s Trial

Posted by MedXY By MedXY 08/07/2025
The ASTER 70s trial found that adding chemotherapy to hormonotherapy did not improve survival but increased toxicity in women aged 70+ with high-risk ER+/HER2- breast cancer.
Read More
Revolutionizing Cancer Therapy: Synergistic Action of Two Natural Bacteria in Complete Tumor Eradication
Posted inClinical Updates news Oncology Specialties

Revolutionizing Cancer Therapy: Synergistic Action of Two Natural Bacteria in Complete Tumor Eradication

Posted by MedXY By MedXY 08/06/2025
A novel bacteria-based therapy using two natural strains demonstrates complete tumor clearance in immunocompromised models, offering hope for cancer patients unsuitable for current immunotherapies.
Read More
Curcumin Shows Promise in Targeting Colorectal Cancer Stem-like Cells: Mechanistic Insights and Clinical Implications
Posted inClinical Updates news Oncology Specialties

Curcumin Shows Promise in Targeting Colorectal Cancer Stem-like Cells: Mechanistic Insights and Clinical Implications

Posted by MedXY By MedXY 08/06/2025
Curcumin, derived from turmeric, targets colorectal cancer stem-like cells, inhibits tumor growth, and promotes differentiation, offering new opportunities for cancer prevention strategies.
Read More
Vitamin C as a Cardioprotective Agent Against Doxorubicin-Induced Cardiotoxicity
Posted inClinical Updates Family Medicine & Nutrition news Oncology Specialties

Vitamin C as a Cardioprotective Agent Against Doxorubicin-Induced Cardiotoxicity

Posted by MedXY By MedXY 08/06/2025
This review explores vitamin C's potential to protect the heart from doxorubicin-induced damage by reducing oxidative stress and preserving cardiac function, highlighting the need for further clinical studies.
Read More
Decoding Oncology Trial Endpoints: OS, DFS, PFS, ORR, CR, PR, SD, PD, and DCR Explained
Posted inClinical Updates news Oncology Specialties

Decoding Oncology Trial Endpoints: OS, DFS, PFS, ORR, CR, PR, SD, PD, and DCR Explained

Posted by MedXY By MedXY 08/06/2025
This article demystifies key clinical trial efficacy endpoints in oncology, including OS, DFS, PFS, ORR, CR, PR, SD, PD, and DCR, providing clinicians with a practical guide to their definitions, roles, and interpretation.
Read More
Beyond Negative: Quantitative Fecal Hemoglobin Levels Refine Colorectal Cancer Risk Stratification in FIT-based Screening
Posted inClinical Updates news Oncology Specialties

Beyond Negative: Quantitative Fecal Hemoglobin Levels Refine Colorectal Cancer Risk Stratification in FIT-based Screening

Posted by MedXY By MedXY 08/06/2025
New meta-analysis reveals a strong dose-response relationship between fecal hemoglobin concentration and colorectal neoplasia risk, even among FIT-negative individuals, supporting personalized screening intervals.
Read More
Overcoming PD-1 Inhibitor Resistance: Six Emerging Strategies from the 2025 ASCO Annual Meeting
Posted inClinical Updates news Oncology Specialties

Overcoming PD-1 Inhibitor Resistance: Six Emerging Strategies from the 2025 ASCO Annual Meeting

Posted by MedXY By MedXY 08/06/2025
PD-1 inhibitor resistance is a major hurdle in cancer immunotherapy. Six leading combination strategies—including chemotherapy, anti-angiogenic agents, radiotherapy, novel checkpoint inhibitors, microbiome modulation, and ADCs—offer new hope for overcoming resistance and improving patient outcomes.
Read More
Alcohol Intake and Pancreatic Cancer: New Global Data Clarifies the Risk
Posted inMedical News news Oncology Specialties

Alcohol Intake and Pancreatic Cancer: New Global Data Clarifies the Risk

Posted by MedXY By MedXY 08/05/2025
A large pooled analysis across continents confirms a linear, dose-dependent association between alcohol consumption and pancreatic cancer risk—independent of smoking status and with significant public health implications.
Read More
Tibremciclib Sets New Benchmark in Advanced HR+/HER2- Breast Cancer: Near Tripling of Progression-Free Survival
Posted inClinical Updates news Oncology Specialties

Tibremciclib Sets New Benchmark in Advanced HR+/HER2- Breast Cancer: Near Tripling of Progression-Free Survival

Posted by MedXY By MedXY 08/05/2025
The TIFFANY phase 3 trial demonstrates tibremciclib plus fulvestrant extends progression-free survival nearly threefold in advanced HR+/HER2- breast cancer following endocrine therapy, with a 63% risk reduction for progression or death and manageable safety.
Read More
A New Era in Refractory Neuroblastoma: First-in-Class Triple Therapy Achieves 75% Disease Control in Children
Posted inClinical Updates news Oncology Specialties

A New Era in Refractory Neuroblastoma: First-in-Class Triple Therapy Achieves 75% Disease Control in Children

Posted by MedXY By MedXY 08/05/2025
A phase I trial published in JCO demonstrates that a novel combination of MIBG, dinutuximab, and vorinostat achieves up to 75% disease control in relapsed/refractory neuroblastoma, offering new hope for high-risk pediatric patients.
Read More
Eradication of Helicobacter pylori Significantly Reduces Gastric Cancer Incidence and Mortality, with Clearer Benefits in High-Risk Populations
Posted inClinical Updates news Oncology Specialties

Eradication of Helicobacter pylori Significantly Reduces Gastric Cancer Incidence and Mortality, with Clearer Benefits in High-Risk Populations

Posted by MedXY By MedXY 08/05/2025
A comprehensive meta-analysis confirms that Helicobacter pylori eradication reduces gastric cancer risk and related deaths, especially benefiting high-risk groups, supporting widespread screening and treatment.
Read More
Cannabis Use Disorder Linked to Elevated Risk of Benign Salivary Gland Tumors: New Insights from a Large Retrospective Cohort Study
Posted inClinical Updates news Oncology Specialties

Cannabis Use Disorder Linked to Elevated Risk of Benign Salivary Gland Tumors: New Insights from a Large Retrospective Cohort Study

Posted by MedXY By MedXY 08/04/2025
A large US-based study found a greater than fivefold increased risk of benign salivary gland tumors, especially parotid tumors, in individuals with cannabis use disorder.
Read More
A Century of Change: How Human Innovation Transformed Lung Cancer Treatment
Posted inClinical Updates news Oncology Specialties

A Century of Change: How Human Innovation Transformed Lung Cancer Treatment

Posted by MedXY By MedXY 08/03/2025
Lung cancer therapy has evolved from rudimentary surgery and misdiagnosis to a precision medicine era, markedly improving outcomes through targeted therapies and immunotherapy.
Read More
Is Your Practice Missing the Next Gastric Cancer Surge?
Posted inMedical News news Oncology Specialties

Is Your Practice Missing the Next Gastric Cancer Surge?

Posted by MedXY By MedXY 08/03/2025
A new study predicts 11.8 million gastric cancer cases linked to Helicobacter pylori infection among children born 2008-2017, urging stronger global prevention and vaccine development.
Read More
Cancer Treatment and Genetic Predisposition Drive Subsequent Neoplasm Risk in Childhood Cancer Survivors
Posted inClinical Updates news Oncology Specialties

Cancer Treatment and Genetic Predisposition Drive Subsequent Neoplasm Risk in Childhood Cancer Survivors

Posted by MedXY By MedXY 08/03/2025
A comprehensive analysis reveals that radiotherapy, chemotherapy, and genetic factors substantially contribute to subsequent neoplasms in long-term childhood cancer survivors, while lifestyle factors play a minimal role.
Read More
Enfortumab Vedotin Plus Pembrolizumab vs Chemotherapy in Untreated Locally Advanced or Metastatic Urothelial Cancer: Patient-Reported Outcomes from the EV-302 Phase 3 Study
Posted inClinical Updates news Oncology Specialties Urology

Enfortumab Vedotin Plus Pembrolizumab vs Chemotherapy in Untreated Locally Advanced or Metastatic Urothelial Cancer: Patient-Reported Outcomes from the EV-302 Phase 3 Study

Posted by MedXY By MedXY 08/03/2025
The EV-302 trial shows enfortumab vedotin plus pembrolizumab improves survival and quality of life over platinum-based chemotherapy in untreated advanced urothelial cancer patients.
Read More
Selumetinib for Adults with NF1-Associated Inoperable Plexiform Neurofibromas: Results from the KOMET Phase 3 Trial
Posted inClinical Updates news Oncology Specialties

Selumetinib for Adults with NF1-Associated Inoperable Plexiform Neurofibromas: Results from the KOMET Phase 3 Trial

Posted by MedXY By MedXY 08/03/2025
The KOMET phase 3 trial shows selumetinib offers significant tumor response in adults with NF1 and inoperable plexiform neurofibromas, with a manageable safety profile.
Read More

Posts pagination

Previous page 1 … 36 37 38 39 40 41 Next page
  • High Glaucoma Risk in Pseudoexfoliation Syndrome: Age and Ocular Hypertension Drive Incidence
  • Post-Thyroidectomy Calcium Strategies: Routine vs. PTH-Guided Supplementation Show Similar Efficacy
  • RAI Outperforms mFI-5 in Predicting Post-UPPP Complications: A Frailty Stratification Breakthrough
  • Robotic Gastrectomy Outperforms Open and Laparoscopic Surgery in Gastric Cancer Outcomes
  • Higher EMS Clinician Trauma Volume Linked to Lower Early Mortality in Trauma Patients
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prevention prostate cancer public health randomized clinical trial randomized trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in